{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:19:58Z","timestamp":1790083198776,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aims to assess oncological outcomes in children and young adults with diffuse infiltrative pontine glioma (DIPG) who have progressed after initial radiotherapy (RT), with an emphasis on the role of re-irradiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data from 33\u00a0patients aged 25\u00a0years or younger with progressive disease after initial RT were retrospectively analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median age at diagnosis was 8\u00a0years (range 4\u201324\u00a0years), and the median initial RT dose was 54\u202fGy (range 39\u201354\u202fGy). The median time between initial RT and progression was 8\u00a0months (range 3\u201340\u00a0months). In addition to systemic therapy, 15\u00a0patients (46%) received re-irradiation due to progression, with a\u00a0median dose of 23.4\u202fGy (range 19.8\u201336\u202fGy), while 18\u00a0patients (54%) were treated with systemic therapy alone. In patients who received re-irradiation after progression, the 1\u2011year post-progression overall survival (OS) was significantly higher compared to those treated with systemic therapy alone (27% vs.\u00a00%, <jats:italic>p<\/jats:italic>\u202f=\u20090.01). Among the 15 re-irradiated patients, 9\u00a0out of 12 with available data (75%) showed improvement in neurological symptoms following re-irradiation. No patient exhibited acute or late RT-related \u2265\u00a0grade\u00a03 toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Palliative re-irradiation in children and young adults with progressive DIPG after initial RT provides an approximately 3\u2011month OS benefit and clinical improvement without significant toxicity and should be considered as a\u00a0standard-of-care approach.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-025-02394-z","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T12:55:21Z","timestamp":1743166521000},"page":"894-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Re-irradiation in progressive diffuse infiltrative pontine glioma in children and young adults"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-2383","authenticated-orcid":false,"given":"Alper","family":"Kahvecioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-8532","authenticated-orcid":false,"given":"Mustafa","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6013-6271","authenticated-orcid":false,"given":"Guzide","family":"Burca Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Tezer Kutluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-2883","authenticated-orcid":false,"given":"Gokcen","family":"Coban Cifci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-6729","authenticated-orcid":false,"given":"Gozde","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"19","key":"2394_CR1","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","volume":"36","author":"LM Hoffman","year":"2018","unstructured":"Hoffman\u00a0LM et\u00a0al (2018) Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a\u00a0collaborative report from the international and european society for pediatric oncology DIPG registries. J\u00a0Clin Oncol 36(19):1963\u20131972","journal-title":"J Clin Oncol"},{"issue":"18","key":"2394_CR2","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1016\/j.ejca.2013.08.006","volume":"49","author":"S Bailey","year":"2013","unstructured":"Bailey\u00a0S et\u00a0al (2013) Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy\u2014results of a\u00a0united kingdom phase\u00a0II trial (CNS 2007 04). Eur J Cancer 49(18):3856\u20133862","journal-title":"Eur J Cancer"},{"issue":"1","key":"2394_CR3","first-page":"68","volume":"8","author":"C Cacciotti","year":"2021","unstructured":"Cacciotti\u00a0C et\u00a0al (2021) Reirradiation practices for children with diffuse intrinsic pontine glioma. Neurooncol Pract 8(1):68\u201374","journal-title":"Neurooncol Pract"},{"issue":"11","key":"2394_CR4","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen\u00a0PY et\u00a0al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J\u00a0Clin Oncol 28(11):1963\u20131972","journal-title":"J Clin Oncol"},{"issue":"3","key":"2394_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11060-018-2991-5","volume":"140","author":"C Kline","year":"2018","unstructured":"Kline\u00a0C et\u00a0al (2018) Reirradiation and PD\u20111 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a\u00a0single-institution experience. J\u00a0Neurooncol 140(3):629\u2013638","journal-title":"J Neurooncol"},{"issue":"1","key":"2394_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11060-019-03140-z","volume":"143","author":"G Fleischhack","year":"2019","unstructured":"Fleischhack\u00a0G et\u00a0al (2019) Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a\u00a0phase\u00a0III clinical study. J\u00a0Neurooncol 143(1):107\u2013113","journal-title":"J Neurooncol"},{"issue":"1","key":"2394_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijrobp.2009.04.031","volume":"77","author":"R Jalali","year":"2010","unstructured":"Jalali\u00a0R et\u00a0al (2010) Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 77(1):113\u2013118","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2394_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/neuonc\/noq205","volume":"13","author":"KJ Cohen","year":"2011","unstructured":"Cohen\u00a0KJ et\u00a0al (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a\u00a0report from the children\u2019s oncology group. Neuro Oncol 13(4):410\u2013416","journal-title":"Neuro Oncol"},{"issue":"2","key":"2394_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11060-011-0681-7","volume":"106","author":"A Chassot","year":"2012","unstructured":"Chassot\u00a0A et\u00a0al (2012) Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J\u00a0Neurooncol 106(2):399\u2013407","journal-title":"J Neurooncol"},{"issue":"10","key":"2394_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi\u00a0ME et\u00a0al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N\u00a0Engl J Med 352(10):997\u20131003","journal-title":"N Engl J Med"},{"issue":"13","key":"2394_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","volume":"42","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany\u00a0I et\u00a0al (2024) ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J\u00a0Clin Oncol 42(13):1542\u20131552","journal-title":"J Clin Oncol"},{"issue":"1","key":"2394_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/COC.0b013e318201a2b7","volume":"35","author":"HP Fontanilla","year":"2012","unstructured":"Fontanilla\u00a0HP et\u00a0al (2012) Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 35(1):51\u201357","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2394_CR13","first-page":"305","volume":"118","author":"M Massimino","year":"2014","unstructured":"Massimino\u00a0M et\u00a0al (2014) Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J\u00a0Neurooncol 118(2):305\u2013312","journal-title":"J Neurooncol"},{"issue":"16","key":"2394_CR14","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2217\/fon-2021-1455","volume":"18","author":"A Elhemaly","year":"2022","unstructured":"Elhemaly\u00a0A et\u00a0al (2022) Palliative and end-of-life symptoms management for children with diffuse intrinsic pontine glioma. Future Oncol 18(16):1943\u20131950","journal-title":"Future Oncol"},{"issue":"8","key":"2394_CR15","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s00381-021-05195-8","volume":"37","author":"PL Zamora","year":"2021","unstructured":"Zamora\u00a0PL, Miller\u00a0SR, Kovoor\u00a0JJ (2021) Single institution experience in re-irradiation of biopsy-proven diffuse intrinsic pontine gliomas. Childs Nerv Syst 37(8):2539\u20132543","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"2394_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijrobp.2018.12.043","volume":"104","author":"MJ Amsbaugh","year":"2019","unstructured":"Amsbaugh\u00a0MJ et\u00a0al (2019) A\u00a0phase\u00a01\/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 104(1):144\u2013148","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2394_CR17","doi-asserted-by":"publisher","first-page":"e26988","DOI":"10.1002\/pbc.26988","volume":"65","author":"A Lassaletta","year":"2018","unstructured":"Lassaletta\u00a0A et\u00a0al (2018) Reirradiation in patients with diffuse intrinsic pontine gliomas: the canadian experience. Pediatr Blood Cancer 65(6):e26988","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2394_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jjco\/hyab006","volume":"51","author":"R Krishnatry","year":"2021","unstructured":"Krishnatry\u00a0R et\u00a0al (2021) Clinical approach to re-irradiation for recurrent diffuse intrinsic pontine glioma. Jpn J Clin Oncol 51(5):762\u2013768","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"2394_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11060-011-0677-3","volume":"106","author":"JE Wolff","year":"2012","unstructured":"Wolff\u00a0JE et\u00a0al (2012) Treatment of recurrent diffuse intrinsic pontine glioma: the MD anderson cancer center experience. J\u00a0Neurooncol 106(2):391\u2013397","journal-title":"J Neurooncol"},{"key":"2394_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2016.12.007","volume":"73","author":"GO Janssens","year":"2017","unstructured":"Janssens\u00a0GO et\u00a0al (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a\u00a0matched-cohort analysis on behalf of the SIOP-E-HGG\/DIPG working group. Eur J Cancer 73:38\u201347","journal-title":"Eur J Cancer"},{"key":"2394_CR21","doi-asserted-by":"crossref","unstructured":"Wawrzuta D et\u00a0al (2024) Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression. Strahlenther Onkol","DOI":"10.1007\/s00066-024-02241-7"},{"key":"2394_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan\u00a0MI, Eisenstat\u00a0DD (2015) DIPG in children\u2014what can we learn from the past? Front Oncol 5:237","journal-title":"Front Oncol"},{"issue":"5","key":"2394_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00381-013-2350-y","volume":"30","author":"S Khatua","year":"2014","unstructured":"Khatua\u00a0S et\u00a0al (2014) Preliminary experience with diffusion tensor imaging before and after re-irradiation treatments in children with progressive diffuse pontine glioma. Childs Nerv Syst 30(5):925\u2013930","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"2394_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.prro.2016.11.005","volume":"7","author":"C Freese","year":"2017","unstructured":"Freese\u00a0C et\u00a0al (2017) Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a\u00a0systematic review of the reirradiation literature. Pract Radiat Oncol 7(2):86\u201392","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"2394_CR25","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1097\/MPH.0000000000000806","volume":"39","author":"ZJ Wang","year":"2017","unstructured":"Wang\u00a0ZJ et\u00a0al (2017) Concomitant use of panobinostat and reirradiation in progressive DIPG: report of 2 cases. J\u00a0Pediatr Hematol Oncol 39(6):e332\u2013e335","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2394_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00381-017-3352-y","volume":"33","author":"A Morales La Madrid","year":"2017","unstructured":"Morales La Madrid\u00a0A et\u00a0al (2017) Second re-irradiation for DIPG progression, re-considering \u201cold strategies\u201d with new approaches. Childs Nerv Syst 33(5):849\u2013852","journal-title":"Childs Nerv Syst"},{"key":"2394_CR27","doi-asserted-by":"publisher","first-page":"926196","DOI":"10.3389\/fonc.2022.926196","volume":"12","author":"L Chavaz","year":"2022","unstructured":"Chavaz\u00a0L et\u00a0al (2022) Neurological symptom improvement after re-irradiation in patients with diffuse intrinsic pontine glioma: a\u00a0retrospective analysis of the SIOP-E-HGG\/DIPG project. Front Oncol 12:926196","journal-title":"Front Oncol"},{"issue":"5","key":"2394_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00381-019-04118-y","volume":"35","author":"VM Lu","year":"2019","unstructured":"Lu\u00a0VM et\u00a0al (2019) Reirradiation for diffuse intrinsic pontine glioma: a\u00a0systematic review and meta-analysis. Childs Nerv Syst 35(5):739\u2013746","journal-title":"Childs Nerv Syst"},{"issue":"5","key":"2394_CR29","doi-asserted-by":"publisher","first-page":"e30929","DOI":"10.1002\/pbc.30929","volume":"71","author":"NP Mankuzhy","year":"2024","unstructured":"Mankuzhy\u00a0NP et\u00a0al (2024) Hypofractionated re-irradiation for diffuse intrinsic pontine glioma. Pediatr Blood Cancer 71(5):e30929","journal-title":"Pediatr Blood Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02394-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:54:20Z","timestamp":1757148860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02394-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2394"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02394-z","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.\u00a0Kahvecioglu, M.\u00a0Cengiz, G.\u00a0Burca Aydin, M.\u00a0Tezer Kutluk, G.\u00a0Coban Cifci, and G.\u00a0Yazici declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the institutional review board (SBA 24\/543 & 05.21.24). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}